EPS společnosti Financière de Tubize SA
Jaká je hodnota metriky EPS společnosti Financière de Tubize SA?
Hodnota metriky EPS společnosti Financière de Tubize SA je 5.85
Jaká je definice metriky EPS?
Zisk na akcii (Eearnings per share - EPS) je zisk společnosti na jednu akcii. Bere v úvahu ředění akcií a počítá se za posledních dvanáct měsíců.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Financière de Tubize SA
Čemu se věnuje společnost Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Firmy s metrikou eps podobnou společnosti Financière de Tubize SA
- Hodnota metriky EPS společnosti Jost's Engineering je 5.84
- Hodnota metriky EPS společnosti Blue Star je 5.85
- Hodnota metriky EPS společnosti Apollo Micro systems je 5.85
- Hodnota metriky EPS společnosti Cambridge Technology Enterprises je 5.85
- Hodnota metriky EPS společnosti AMGEN je 5.85
- Hodnota metriky EPS společnosti WEX Inc je 5.85
- Hodnota metriky EPS společnosti Financière de Tubize SA je 5.85
- Hodnota metriky EPS společnosti Northern Oil and Gas je 5.86
- Hodnota metriky EPS společnosti Stef S.A je 5.86
- Hodnota metriky EPS společnosti Westlife Development je 5.86
- Hodnota metriky EPS společnosti Northern Oil and Gas je 5.86
- Hodnota metriky EPS společnosti J.B. Hunt Transport Services je 5.86
- Hodnota metriky EPS společnosti e Crit SA je 5.86